SanBio Company Limited
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/09/13 | ¥-4.80 | ¥-12.24 | -155.2% |
| 2026/03/17 | ¥-20.69 | ¥-14.80 | +28.5% |
| 2025/12/15 | ¥-15.35 | ¥-9.95 | +35.2% |
| 2018/12/14 | ¥-16.10 | ¥-10.18 | +36.8% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
iShares Trust-iShares Core MSCI EAFE ETF
|
452.5K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
206.3K | -13.25% | |
|
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E
|
187.5K | 0.00% | |
|
iShares Trust-iShares Core MSCI International Developed Markets ETF
|
85.7K | 0.00% | |
|
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota
|
41.2K | -76.44% | |
|
Fidelity Salem Street Trust-Fidelity Total International Index Fund
|
40.9K | +40.55% |
Financial Performance
2026/10/04 UpdatedNo financial data available
Latest IR Information
-
Earnings Briefing
Announces 2Q of the fiscal year ending January 2027. Revenue is undisclosed; focuses on changes in costs centered on R&D expenses, with an improvement in operating loss. Outlines post-AQUGO (Auguo) launch adoption and strengthened supply chains, accelerated U.S. expansion, and...
Read more -
Notice on the recognition of other income, other expenses and adjustments to corporate taxes, etc.
Recognized foreign exchange gains of 185 million yen, interest income of 22 million yen, financing expenses of 11 million yen, bond interest of 16 million yen, and adjustments to corporate taxes of 58 million yen. Refer to the consolidated quarterly...
Read more -
Notice on Differences Between Consolidated Earnings Forecast for the Second Quarter of the Fiscal Year Ending January 2027 and Actual Results
Disclosure of the differences between the consolidated earnings forecast for the second quarter of the fiscal year ending January 2027 and actual results. Operating loss decreased due to revision of manufacturing cost recognition timing and inventory capitalization accompanying drug price...
Read more -
FY2027 1st quarter 2Q Interim Financial Results Summary (Japanese GAAP) (Consolidated)
Operating loss primarily due to commercialization costs for SB623 and manufacturing and sales approval-related expenses for Akugo; however, ordinary income improved due to foreign exchange gains. The full-year FY2027 outlook is as disclosed, and dividend guidance is undecided. Financial position...
Read more -
Corrected Notice on Domestic Integration of ACGO® Production System Following Minaris USA Factory Closure
In response to Minaris’ US factory closure, ACGO® production will be domestically integrated. Upstream processes will be transferred to the Yokohama Factory to establish a vertically integrated manufacturing system. We will advance dual-track production to enhance manufacturing stability and supply...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,560
Rating Score: 2.60 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
